FDA should disclose new drug agreements and response letters - STAT

FDA should disclose new drug agreements and response letters - STAT

Hiding in plain sight: The FDA’s approach to disclosing new drug applications is a disservice to public health

By PETER G. LURIE

ADOBE

The FDA doesn't disclose new drug applications, treating them as confidential commercial information, even though the applicants routinely publicize them.

READ MORE